Sell-side Analyst Weighing in on These Shares: Glu Mobile Inc. (NASDAQ:GLUU), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

June 27, 2017

Research analysts covering Glu Mobile Inc. (NASDAQ:GLUU) are projecting that the shares reach $3.012 within the next 12-18 months.  This is the consensus number derived from the 4 analyst reports taken into consideration. The most bullish, or aggressive analyst target pins the projected price at $3.75, while the most bearish, or conservative analyst sees the stock reaching $2.5.

Broker Rating Update on Glu Mobile Inc. (NASDAQ:GLUU)

Zacks provides analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Shares of Glu Mobile Inc. (NASDAQ:GLUU) currently have an ABR of 1.8. This is based on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.  Moving to earnings estimates, for this current fiscal period, Wall Street analysts have projected that the company will post $-0.13 earnings per share. This is the current Zacks consensus EPS which was calculated at the time of writing. Analysts will likely revise their estimates leading in to the actual results date.  

taking a look at the most recent period, which closed on 2017-03-31, Glu Mobile Inc. reported EPS of $-0.17 for a surprise factor of -88.89%, calculated by being $-0.08 away from analyst projections.

Investors will be marking their calendars for 2017-08-01, when the company is planning to release their quarterly results.

For the current quarter, analysts are expecting Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report EPS of $1.08. This consensus estimate is provided by Zacks Research. After the period that ended on 2017-03-31, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) reported an EPS actual of $1.2. The difference between the actual and estimate resulted in a surprise factor of 14.29%. The company is expected to release their next earnings report on or around 2017-07-27. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have a current ABR or average broker rating of 1.63. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.

Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is $155.692. The top analyst target is $180, and the lowest target is $120 on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

By DR Staff Writer

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter:

Latest Stories